CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Nod for SGLT-2 Inhibitor and Metformin Combo for Type 2 Diabetes

CompanyMedical Device

MicroPort CardioFlow Medtech’s AnchorMan System Receives NMPA Approval as First Semi-Closed LAA Occluder in China

CompanyDeals

Ningbo Linstant Polymer Materials Secures Over USD 14 Million in Series B Financing to Boost Production and Global Reach

CompanyDeals

Lion TCR Partners with MaxCyte to Develop mRNA-Based TCR-T Therapies for Solid Tumors and Viral Diseases

CompanyDeals

OnCusp Therapeutics Secures Oversubscribed USD 100 Million Series A Financing for CDH6-Targeting ADC

CompanyDeals

Merck In-Licenses Inspirna’s Ompenaclid for Advanced Colorectal Cancer, Eyes Market Potential

CompanyDeals

Boehringer Ingelheim Teams Up with 3T Biosciences for Next-Gen T-Cell Cancer Therapies

CompanyDeals

Novo Nordisk Expands U.S. Ties, Collaborates with Flagship Pioneering on Cardiometabolic Advances

CompanyDeals

Menarini’s Stemline Signs $500M+ License with Insilico for Cancer Drug Candidate

CompanyDrug

Genrix Bio Seeks China Approval for New Xeligekimab Use in Axial Spondyloarthritis

Policy / Regulatory

Shanghai Pharmaceuticals’ Subsidiary Reprimanded Again for Monopolisitic Pricing of Polymyxin B Sulfate

CompanyDrug

Akeso Biopharma Submits New Indication Application for Cadonilimab in Gastric Cancer Treatment